|
n (%)
|
MACC1-AS1
|
MACC1
|
|---|
|
Low and negative (n)
|
High (n)
|
P
|
Low and Negative (n)
|
High (n)
|
P
|
|---|
|
Age (years)
| | |
0.752
| | |
0.803
|
|
≥55
|
72(58.5%)
|
43
|
29
| |
45
|
27
| |
|
<55
|
51(41.5%)
|
29
|
22
| |
33
|
18
| |
|
Sex
| | | |
0.351
| | | |
|
Male
|
76(61.8%)
|
42
|
34
| |
45
|
31
|
0.22
|
|
Female
|
47(38.2%)
|
30
|
17
| |
33
|
14
| |
|
TNM stage
| | |
0.022*
| | |
0.002**
|
|
I
|
17(13.8%)
|
15
|
2
| |
14
|
3
| |
|
II
|
25(20.3%)
|
14
|
11
| |
19
|
6
| |
|
III
|
43(35.0%)
|
25
|
18
| |
28
|
15
| |
|
IV
|
38(30.9%)
|
18
|
20
| |
17
|
21
| |
|
Tumor invasion
| | |
0.024*
| | |
0.135
|
|
T1
|
12(9.8%)
|
10
|
2
| |
9
|
3
| |
|
T2
|
14(11.4%)
|
10
|
4
| |
11
|
3
| |
|
T3
|
50(40.7%)
|
29
|
21
| |
31
|
19
| |
|
T4
|
47(38.2%)
|
23
|
24
| |
27
|
20
| |
|
Lymph node metastasis
| | |
0.004**
| | |
0.034*
|
|
N0
|
29(23.6%)
|
22
|
7
| |
13
|
13
| |
|
N1
|
34(27.7%)
|
20
|
14
| |
20
|
14
| |
|
N2
|
34(27.7%)
|
22
|
12
| |
23
|
11
| |
|
N3
|
26(21.1%)
|
8
|
18
| |
22
|
7
| |
|
Distant metastasis
| | |
0.065
| | |
0.055
|
|
M0
|
101(82.1%)
|
63
|
38
| |
68
|
33
| |
|
M1
|
22(17.9%)
|
9
|
13
| |
10
|
12
| |
|
Tumor differentiation
| | |
0.963
| | |
0.923
|
|
Well
|
6(4.9%)
|
5
|
1
| |
5
|
1
| |
|
Moderate
|
20(16.3%)
|
10
|
10
| |
11
|
9
| |
|
Poor
|
97(78.9%)
|
57
|
40
| |
62
|
35
| |
|
Mortality
| | |
0.213
| | |
0.138
|
|
Survive
|
13(34.2%)
|
8
|
5
| |
8
|
5
| |
|
die
|
25(65.8%)
|
10
|
15
| |
9
|
16
| |
|
Recurrence
| | |
0.012*
| | |
0.114
|
|
No
|
40(47.1%)
|
31
|
9
| |
32
|
8
| |
|
Yes
|
45(52.9%)
|
23
|
22
| |
29
|
16
| |
